CA2362427A1 - Compositions et methodes de traitement des maladies immunitaires - Google Patents

Compositions et methodes de traitement des maladies immunitaires Download PDF

Info

Publication number
CA2362427A1
CA2362427A1 CA002362427A CA2362427A CA2362427A1 CA 2362427 A1 CA2362427 A1 CA 2362427A1 CA 002362427 A CA002362427 A CA 002362427A CA 2362427 A CA2362427 A CA 2362427A CA 2362427 A1 CA2362427 A1 CA 2362427A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
acid sequence
antibody
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002362427A
Other languages
English (en)
Inventor
Avi J. Ashkenazi
Kevin P. Baker
Audrey Goddard
Austin L. Gurney
Caroline Hebert
William Henzel
Rhona C. Kabakoff
Yanmei Lu
James Pan
Diane Pennica
David L. Shelton
Victoria Smith
Timothy A. Stewart
Daniel Tumas
Colin K. Watanabe
William I. Wood
Minhong Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/005028 external-priority patent/WO1999046281A2/fr
Priority claimed from PCT/US1999/008615 external-priority patent/WO1999055868A2/fr
Priority claimed from PCT/US1999/012252 external-priority patent/WO1999063088A2/fr
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/fr
Priority claimed from PCT/US1999/020594 external-priority patent/WO2000015666A2/fr
Priority claimed from PCT/US1999/020944 external-priority patent/WO2000015792A2/fr
Priority claimed from PCT/US1999/021547 external-priority patent/WO2000015797A2/fr
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/fr
Priority claimed from PCT/US1999/023089 external-priority patent/WO2000021996A2/fr
Priority claimed from PCT/US1999/028214 external-priority patent/WO2001019987A1/fr
Priority claimed from PCT/US1999/028409 external-priority patent/WO2000032778A2/fr
Priority claimed from PCT/US1999/028313 external-priority patent/WO2000032221A2/fr
Priority claimed from PCT/US1999/028634 external-priority patent/WO2000036102A2/fr
Priority claimed from PCT/US1999/028301 external-priority patent/WO2000032776A2/fr
Priority claimed from PCT/US1999/028565 external-priority patent/WO2000037638A2/fr
Priority claimed from PCT/US1999/028551 external-priority patent/WO2000053750A1/fr
Priority claimed from PCT/US1999/028564 external-priority patent/WO2000055319A1/fr
Priority claimed from PCT/US1999/030095 external-priority patent/WO2000037640A2/fr
Priority claimed from PCT/US1999/030999 external-priority patent/WO2001005836A1/fr
Priority claimed from PCT/US1999/031274 external-priority patent/WO2000053752A2/fr
Priority claimed from PCT/US2000/000219 external-priority patent/WO2000053753A2/fr
Priority claimed from PCT/US2000/000376 external-priority patent/WO2000053755A2/fr
Priority claimed from PCT/US2000/000277 external-priority patent/WO2000053754A1/fr
Priority claimed from PCT/US2000/003565 external-priority patent/WO2001053486A1/fr
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/fr
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/fr
Priority claimed from PCT/US2000/004414 external-priority patent/WO2001004311A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2362427A1 publication Critical patent/CA2362427A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)

Abstract

Cette invention concerne une composition renfermant de nouvelles protéines, et des méthodes de diagnostic et de traitement de maladies immunitaires.
CA002362427A 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires Abandoned CA2362427A1 (fr)

Applications Claiming Priority (79)

Application Number Priority Date Filing Date Title
USPCT/US99/05028 1999-03-08
PCT/US1999/005028 WO1999046281A2 (fr) 1998-03-10 1999-03-08 Nouveaux polypeptides et acides nucleiques les codant
US12361899P 1999-03-10 1999-03-10
US60/123,618 1999-03-10
US12395799P 1999-03-12 1999-03-12
US60/123,957 1999-03-12
US12577599P 1999-03-23 1999-03-23
US60/125,775 1999-03-23
US12884999P 1999-04-12 1999-04-12
US60/128,849 1999-04-12
USPCT/US99/08615 1999-04-20
PCT/US1999/008615 WO1999055868A2 (fr) 1998-04-24 1999-04-20 Proteines fizz
US13144599P 1999-04-28 1999-04-28
US60/131,445 1999-04-28
US13237199P 1999-05-04 1999-05-04
US60/132,371 1999-05-04
US13428799P 1999-05-14 1999-05-14
US60/134,287 1999-05-14
USPCT/US99/12252 1999-06-02
PCT/US1999/012252 WO1999063088A2 (fr) 1998-06-02 1999-06-02 Proteines membranaires et acides nucleiques codant ces proteines
US14103799P 1999-06-23 1999-06-23
US60/141,037 1999-06-23
US14475899P 1999-07-20 1999-07-20
US60/144,758 1999-07-20
US14569899P 1999-07-26 1999-07-26
US60/145,698 1999-07-26
US14622299P 1999-07-28 1999-07-28
US60/146,222 1999-07-28
USPCT/US99/20111 1999-09-01
PCT/US1999/020111 WO2000012708A2 (fr) 1998-09-01 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes
USPCT/US99/20594 1999-09-08
PCT/US1999/020594 WO2000015666A2 (fr) 1998-09-10 1999-09-08 Compositions et methodes de traitement des tumeurs
PCT/US1999/020944 WO2000015792A2 (fr) 1998-09-14 1999-09-13 Promotion ou inhibition d'angiogenese et de cardiovascularisation
USPCT/US99/20944 1999-09-13
PCT/US1999/021547 WO2000015797A2 (fr) 1998-09-17 1999-09-15 Compositions et methodes de traitement des maladies relatives au syteme immunitaire
USPCT/US99/21090 1999-09-15
USPCT/US99/21547 1999-09-15
PCT/US1999/021090 WO2000015796A2 (fr) 1998-09-16 1999-09-15 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US1999/023089 WO2000021996A2 (fr) 1998-10-13 1999-10-05 Procedes et compositions inhibant la croissance des cellules neoplasiques
USPCT/US99/23089 1999-10-05
US16250699P 1999-10-29 1999-10-29
US60/162,506 1999-10-29
USPCT/US99/28214 1999-11-29
PCT/US1999/028214 WO2001019987A1 (fr) 1999-09-13 1999-11-29 Promotion ou inhibition de l'angiogenese et de la vascularisation cardiaque
PCT/US1999/028409 WO2000032778A2 (fr) 1998-12-01 1999-11-30 Methodes et compositions permettant d'inhiber la croissance de cellules neoplasiques
USPCT/US99/28409 1999-11-30
PCT/US1999/028313 WO2000032221A2 (fr) 1998-12-01 1999-11-30 Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
USPCT/US99/28313 1999-11-30
USPCT/US99/28301 1999-12-01
USPCT/US99/28634 1999-12-01
PCT/US1999/028634 WO2000036102A2 (fr) 1998-12-16 1999-12-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
PCT/US1999/028301 WO2000032776A2 (fr) 1998-12-01 1999-12-01 Polypeptides secretes et transmembranaires et acides nucleiques les codant
USPCT/US99/28565 1999-12-02
USPCT/US99/28551 1999-12-02
PCT/US1999/028565 WO2000037638A2 (fr) 1998-12-22 1999-12-02 Methodes permettant d'inhiber la croissance de cellules neoplasiques
USPCT/US99/28564 1999-12-02
PCT/US1999/028551 WO2000053750A1 (fr) 1999-03-08 1999-12-02 Compositions et procedes pour le traitement de tumeurs
PCT/US1999/028564 WO2000055319A1 (fr) 1999-03-12 1999-12-02 Procedes et compositions pour inhiber la croissance des cellules neoplasiques
USPCT/US99/30095 1999-12-16
PCT/US1999/030095 WO2000037640A2 (fr) 1998-12-22 1999-12-16 Compositions et methodes de traitement d'une tumeur
USPCT/US99/30999 1999-12-20
PCT/US1999/030999 WO2001005836A1 (fr) 1999-07-20 1999-12-20 Compositions polypeptidiques et methodes de traitement des tumeurs
USPCT/US99/31274 1999-12-30
PCT/US1999/031274 WO2000053752A2 (fr) 1999-03-08 1999-12-30 Activation ou inhibition de l'angiogenese et de la cardiovascularisation
PCT/US2000/000219 WO2000053753A2 (fr) 1999-03-08 2000-01-05 Activation ou inhibition de l'angiogenese et de la cardiovascularisation
USPCT/US00/00219 2000-01-05
PCT/US2000/000376 WO2000053755A2 (fr) 1999-03-08 2000-01-06 Compositions et procedes pour le traitement de tumeur
PCT/US2000/000277 WO2000053754A1 (fr) 1999-03-08 2000-01-06 Compositions et methodes pour le traitement de tumeurs
USPCT/US00/00376 2000-01-06
USPCT/US00/00277 2000-01-06
PCT/US2000/003565 WO2001053486A1 (fr) 1999-03-08 2000-02-11 Compositions et procedes destines au traitement de tumeur
USPCT/US00/03565 2000-02-11
USPCT/US00/04341 2000-02-18
PCT/US2000/004342 WO2000078961A1 (fr) 1999-06-23 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
PCT/US2000/004341 WO2000053756A2 (fr) 1999-03-08 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
USPCT/US00/04342 2000-02-18
PCT/US2000/004414 WO2001004311A1 (fr) 1999-07-07 2000-02-22 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US00/04414 2000-02-22
PCT/US2000/005841 WO2000053758A2 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires

Publications (1)

Publication Number Publication Date
CA2362427A1 true CA2362427A1 (fr) 2000-09-14

Family

ID=32831300

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002362427A Abandoned CA2362427A1 (fr) 1999-03-08 2000-03-02 Compositions et methodes de traitement des maladies immunitaires

Country Status (6)

Country Link
EP (1) EP1220905A2 (fr)
JP (1) JP2004516227A (fr)
KR (1) KR20010103046A (fr)
AU (1) AU3514400A (fr)
CA (1) CA2362427A1 (fr)
WO (1) WO2000053758A2 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6590088B1 (en) 1996-07-19 2003-07-08 Human Genome Sciences, Inc. CD33-like protein
US7285267B2 (en) 1997-01-14 2007-10-23 Human Genome Sciences, Inc. Tumor necrosis factor receptors 6α & 6β
DE69837996T2 (de) 1997-01-14 2008-02-28 Human Genome Sciences, Inc. Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
JP3492999B2 (ja) 1997-08-26 2004-02-03 ザイモジェネティクス，インコーポレイティド 脂肪細胞特異的タンパク質の同族体
WO1999012963A2 (fr) 1997-09-12 1999-03-18 Biogen, Inc. Recepteurs 'trail' riches en cysteine
PT1015587E (pt) 1997-09-18 2008-07-31 Genentech Inc Polipéptido dcr3, um homólogo de tnfr
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
US20030187191A1 (en) * 1998-09-01 2003-10-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6924355B2 (en) * 1998-09-01 2005-08-02 Genentech, Inc. PRO1343 polypeptides
US7026448B2 (en) * 1998-09-01 2006-04-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6972186B2 (en) * 1998-09-23 2005-12-06 Genentech, Inc. Nucleic acid encoding pro 1410 polypeptides
US7083946B2 (en) * 1998-09-23 2006-08-01 Genentech, Inc. PRO1343 nucleic acids
US6960433B1 (en) 1998-10-19 2005-11-01 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
US6432673B1 (en) 1998-12-07 2002-08-13 Zymogenetics, Inc. Growth factor homolog ZVEGF3
CA2365913C (fr) 1999-04-12 2015-03-03 Genentech, Inc. Homologues recepteurs de facteur de necrose tumorale et acides nucleiques les codant
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US6951738B2 (en) 1999-07-16 2005-10-04 Human Genome Sciences, Inc. Human tumor necrosis factor receptors TR13 and TR14
WO2001023553A2 (fr) * 1999-09-29 2001-04-05 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts C4.4a, un nouvel antigène associée à la métastase
CA2391820A1 (fr) 1999-10-22 2001-05-03 Zymogenetics, Inc. Polypeptides umlr
US7119165B2 (en) 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
HUP0203863A3 (en) * 2000-01-12 2008-03-28 Univ Yale Nogo receptor-mediated blockade of axonal growth
AU2001241166A1 (en) * 2000-03-16 2001-09-24 Kyowa Hakko Kogyo Co. Ltd. Kidney repairing factor
EP1325130B1 (fr) 2000-10-06 2010-02-24 Yale University Homologues du recepteur de nogo
US20020111302A1 (en) * 2000-11-30 2002-08-15 Y. Tom Tang Novel nucleic acids and polypeptides
JP2005502317A (ja) * 2001-03-22 2005-01-27 ジェネンテック・インコーポレーテッド ボールカインポリペプチド及び核酸
EP2280030A3 (fr) 2001-04-10 2011-06-15 Agensys, Inc. Acides nucléiques et protéines correspondantes utiles dans la détection et le traitement des différents cancers
JP4181032B2 (ja) 2001-05-25 2008-11-12 アムジェン インコーポレーテッド Ｂ７関連タンパク質−２分子およびその使用
AU2002315404A1 (en) * 2001-07-16 2003-03-03 Eli Lilly And Company Extracellular junctional adhesion molecules
WO2003013583A1 (fr) * 2001-08-10 2003-02-20 Genset S.A. Agonistes et antagonistes de faxigene dans le traitement de troubles metaboliques
EP1541677A4 (fr) 2002-07-10 2007-06-27 Takeda Pharmaceutical Nouvelles proteines et leur utilisation
EP2277532A1 (fr) 2002-09-11 2011-01-26 Genentech, Inc. Nouvelles compositions et procédés pour le traitement de maladies liées au système immunitaire
US20050283842A1 (en) * 2002-10-02 2005-12-22 Karsten Eulenberg Mipp1 homologous nucleic acids and proteins involved in the regulation of energy homeostatis
EP1576137A4 (fr) * 2002-10-29 2010-06-30 Genentech Inc Compositions et methodes de traitement de maladies liees au systeme immunitaire
EP1578367A4 (fr) * 2002-11-01 2012-05-02 Genentech Inc Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
WO2005051988A2 (fr) * 2003-03-03 2005-06-09 Genentech, Inc. Compositions et procedes permettant de traiter un lupus erythemateux systemique
EP1744620A2 (fr) * 2004-05-12 2007-01-24 Genentech, Inc. Nouvelles disruptions geniques, compositions et methodes associees
WO2006017673A2 (fr) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Influence du taj sur les fonctions neuronales
JP4897690B2 (ja) * 2004-10-12 2012-03-14 ジェネンテック， インコーポレイテッド 補体関連障害の予防および処置のためのＣＲＩｇポリペプチド
WO2007008732A2 (fr) 2005-07-07 2007-01-18 Yale University Compositions et procedes pour supprimer l'inhibition de la croissance axonale
PT2500030E (pt) 2005-11-04 2015-09-24 Genentech Inc Uso de inibidores da via do complemento para tratar doenças oculares
PL2907827T3 (pl) 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
EP3208612B1 (fr) 2008-04-09 2019-09-18 Genentech, Inc. Compositions et procédés pour le traitement de maladies liées au système immunitaire
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
WO2009137605A2 (fr) 2008-05-06 2009-11-12 Genentech, Inc. Variants de crig à maturation d'affinité
EP2494351B1 (fr) * 2009-10-26 2016-06-08 Externautics S.p.A. Marqueurs de tumeurs du rectum et du côlon, et leurs méthodes d'utilisation
WO2011051271A2 (fr) 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeur de la prostate et méthodes d'utilisation
EP2494361B2 (fr) 2009-10-26 2019-01-09 Externautics S.p.A. Marqueurs de tumeurs des ovaires et leurs méthodes d'utilisation
TWI888366B (zh) 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
KR20160147855A (ko) 2014-05-01 2016-12-23 제넨테크, 인크. 항-인자 d 항체 변이체 및 이의 용도
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
PH12022553648A1 (en) 2015-09-25 2024-03-11 Genentech Inc Anti-tigit antibodies and methods of use
EP3368074A2 (fr) 2015-10-30 2018-09-05 Hoffmann-La Roche AG Anticorps et conjugués anti-facteur d
HK1257422A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 抗-因子d抗体变体缀合物及其用途
JP7589982B2 (ja) 2020-12-25 2024-11-26 学校法人北里研究所 ペプチド及びその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014772A1 (fr) * 1993-11-12 1995-06-01 Kenichi Matsubara Signature genique
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US5874230A (en) * 1996-07-10 1999-02-23 Tularik, Inc. Assays using TRAF2-associated protein kinase polypeptides
WO1998011138A1 (fr) * 1996-09-12 1998-03-19 Human Genome Sciences, Inc. Chimiokine alpha-4
WO1999046281A2 (fr) * 1998-03-10 1999-09-16 Genentech, Inc. Nouveaux polypeptides et acides nucleiques les codant
AU5383498A (en) * 1996-12-05 1998-06-29 Human Genome Sciences, Inc. Human chemokine beta-13
WO1999037671A1 (fr) * 1998-01-27 1999-07-29 Eli Lilly And Company Gene et proteine associes au facteur de croissance des cellules endotheliales vasculaires
ES2389387T3 (es) * 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
JP2002520068A (ja) * 1998-07-15 2002-07-09 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 骨形態形成タンパク質
CA2354325C (fr) * 1998-12-07 2011-08-16 Zymogenetics, Inc. Zvegf3 homologue du facteur de croissance

Also Published As

Publication number Publication date
AU3514400A (en) 2000-09-28
EP1220905A2 (fr) 2002-07-10
WO2000053758A3 (fr) 2001-02-08
WO2000053758A2 (fr) 2000-09-14
KR20010103046A (ko) 2001-11-17
JP2004516227A (ja) 2004-06-03

Similar Documents

Publication Publication Date Title
AU3514400A (en) Compositions and methods for the treatment of immune related diseases
CA2503125C (fr) Nouvelle composition et procedes pour le traitement de maladies auto-immunes
CA2373915A1 (fr) Procedes et compositions visant a inhiber la proliferation des cellules cancereuses
EP1309620A2 (fr) Compositions et procedes de diagnose et traitement de maladies faisant intervenir l'angiogenese
CA2498008A1 (fr) Nouvelles composition et methodes servant au traitement de maladies associees au systeme immunitaire
CA2347835A1 (fr) Promotion et inhibition de l'angiogenese et de la vascularisation cardiaque
US20080038264A1 (en) Compositions and methods for the treatment of immune related diseases
CA2353799A1 (fr) Methodes permettant d'inhiber la croissance de cellules neoplasiques
WO2002008284A2 (fr) Compositions et methodes diagnostiques et therapeutiques de troubles impliquant l'angiogenese
US7282570B2 (en) Compositions and methods for the treatment of immune related diseases
CA2375458A1 (fr) Compositions et methodes pour traiter des maladies d'ordre immunologique
CA2497334A1 (fr) Nouvelles compositions et methodes pour le traitement de maladies associees au systeme immunitaire
US7282562B2 (en) Compositions and methods for the treatment of immune related diseases
CA2497661A1 (fr) Compositions et methodes pour le traitement de maladies du systeme immunitaire
CA2348157A1 (fr) Methodes et compositions permettant d'inhiber la croissance de cellules neoplasiques
CA2390786A1 (fr) Compositions et procedes de traitement de maladies d'ordre immunologique
CA2343006A1 (fr) Compositions et methodes de traitement des maladies relatives au syteme immunitaire
US7601514B2 (en) Nucleic acid encoding PRO10268 polypeptides
US7381809B2 (en) Compositions and methods for the treatment of immune related diseases
WO2001066740A2 (fr) Compositions et methodes de traitement de maladies d'origine immune
CA2384055A1 (fr) Compositions et procedes pour le traitement de maladies d'ordre immunologique
US7307153B2 (en) Antibodies that bind PRO9912
US7344880B2 (en) Nucleic acid encoding PRO9912 polypeptides
WO2001019991A1 (fr) Compositions et techniques permettant de traiter des maladies d'origine immunologique
EP1878795A2 (fr) Compositions et procédés pour le traitement de maladies liées au système immunitaire

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead